��������

Faye Woolf is the current owner and CEO of Aperio Clinical Outcomes, a clinical research outcomes organization (CROO) managing Phase I-IV clinical trials across a broad range of therapeutic areas. Faye co-founded the company in 2013 and has been instrumental in its success, helping biotechnology, pharmaceutical and device companies bring their products to market as quickly and economically as possible.

Prior to Aperio, Faye co-founded Trio Clinical Research in 2003 and served as its president until 2009. Trio was a full-service contract research organization (CRO) that provided comprehensive clinical development services to the biopharmaceutical and medical device industries.

Faye began their career in 1992 with the co-founding of The Woolf Group, a successful clinical research management consulting firm. As CEO of The Woolf Group for 10 years, Faye helped numerous biotech and pharmaceutical companies streamline their clinical development processes, saving time and money while ensuring compliance with regulations.

Faye's experience and expertise in the clinical research field are unmatched, and their commitment to helping others bring life-changing treatments to market is evident in all that they do.

Some direct reports include Connor Edlefsen - Director, Budgets & Proposals, Lori Banctel - Director, Risk Based Quality Management, and Lisa Jamba - Director, Programming.